Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $64.99$44.00 | $8.80/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| 06-01260229 | Feb 2026 | 99.9% | MZ Biolabs | — | Unverified | View |
| — | Jul 2024 | 99.8% | MZ Biolabs | — | Unverified |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. Ipamorelin is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Ascension Peptides sell Ipamorelin?
Yes — Ascension Peptides currently lists Ipamorelin in 1 variant starting at $44.00 ($8.80/mg).
Is Ascension Peptides's Ipamorelin third-party tested?
Yes — Disclosed Labs has indexed 2 Certificates of Analysis for Ascension Peptides's Ipamorelin, with the most recent showing 99.9% purity. Ascension Peptides holds an overall trust grade of C (71/100) across all 11 COAs on file.
What is Ascension Peptides's trust grade for Ipamorelin?
Ascension Peptides has an overall Disclosed Labs trust grade of C (71/100), computed from 11 COAs across all peptides. The most recent Ipamorelin COA was issued by MZ Biolabs.
Where is the cheapest Ipamorelin?
As of the latest data, Peptide Supply Co. offers Ipamorelin at $2.70/mg — compare with Ascension Peptides's listing at $8.80/mg. See the full Ipamorelin price comparison.
Is Ipamorelin legal to buy?
Ipamorelin is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| View |
Disclosed Labs